Objective: Rosacea is a chronic cutaneous disorder characterized by flushing, erythema, telangiectasia, edema, papules, and pustules. The cause of this inflammatory disorder is unknown, but is thought to be multifaceted. Primary treatments for rosacea are typically oral antibiotics and topical therapies. Hyaluronic acid sodium salt cream 0.2% is a topical device containing low molecular weight hyaluronic acid (LMW-HA) that is effective in normalizing the cutaneous inflammatory response. The objective of this study was to evaluate the efficacy and safety of hyaluronic acid sodium salt cream 0.2%.
Design and setting: Prospective, observational, non-blinded efficacy and tolerability study in an outpatient setting.
Participants: Individuals 18 to 75 years of age with mild to moderate facial rosacea.
Measurements: Outcome measures included papules, pustules, erythema, edema, telangiectasia, burning or stinging, dryness and provider global assessment (PGA), which were all measured on a five-point scale. Subjects were assessed at baseline, week 2, week 4, and week 8.
Results: Final data for 14 of 15 subjects are presented. Through visual grading assessments, hyaluronic acid sodium salt cream 0.2% was shown to improve the provider global assessment by 47.5 percent from baseline to week 4. Reductions in papules, erythema, burning or stinging, and dryness were 47, 51.7, 65, and 78.8 percent, respectively at week 4. At week 8, the provider global assessment was improved from baseline in 78.5 percent of subjects.
Conclusion: Improvement was noted in measured clinical parameters with use of topical low molecular weight hyaluronic acid. Topical low molecular weight hyaluronic acid is another option that may be considered for the treatment of rosacea in the adult population. Compliance and tolerance were excellent. Consideration should be given to use for individuals with rosacea characterized by an erythematous and/or papular component.
An open-label pilot study to evaluate the safety and efficacy of topically applied pimecrolimus cream for the treatment of steroid-induced rosacea-like eruption.
Chu CY. Chu CY. J Eur Acad Dermatol Venereol. 2007 Apr;21(4):484-90. doi: 10.1111/j.1468-3083.2006.01991.x. J Eur Acad Dermatol Venereol. 2007. PMID: 17373975 Clinical Trial.
A randomized, single-blind, placebo-controlled, split-face study with pimecrolimus cream 1% for papulopustular rosacea.
Karabulut AA, Izol Serel B, Eksioglu HM. Karabulut AA, et al. J Eur Acad Dermatol Venereol. 2008 Jun;22(6):729-34. doi: 10.1111/j.1468-3083.2008.02589.x. Epub 2008 Mar 3. J Eur Acad Dermatol Venereol. 2008. PMID: 18328059 Clinical Trial.
Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies.
Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, Appell M, Steinhoff M, Lynde C, Liu H, Jacovella J. Stein L, et al. J Drugs Dermatol. 2014 Mar;13(3):316-23. J Drugs Dermatol. 2014. PMID: 24595578 Clinical Trial.
Topical rosacea therapy: the importance of vehicles for efficacy, tolerability and compliance.
Jackson JM, Pelle M. Jackson JM, et al. J Drugs Dermatol. 2011 Jun;10(6):627-33. J Drugs Dermatol. 2011. PMID: 21637903 Review.
Azelaic acid (15% gel) in the treatment of acne rosacea.
Gupta AK, Gover MD. Gupta AK, et al. Int J Dermatol. 2007 May;46(5):533-8. doi: 10.1111/j.1365-4632.2005.02769.x. Int J Dermatol. 2007. PMID: 17472690 Review.
Cited by 5 articles
A Split-Face Study Assessing the Clinical Benefit, Tolerability and Subject Satisfaction of a Dermocosmetic in Subjects with Rosacea Associated with Erythema and Sensitive Skin.
Berardesca E, Bonfigli A, Cribier B, Flament F, Vicic M, Kerob D, Tan J. Berardesca E, et al. Clin Cosmet Investig Dermatol. 2020 Oct 5;13:751-758. doi: 10.2147/CCID.S266879. eCollection 2020. Clin Cosmet Investig Dermatol. 2020. PMID: 33116738 Free PMC article.
A Preliminary Clinical Evaluation of a Topical Product for Reducing Slight Rosacea Imperfections.
Maggioni D, Cimicata A, Praticò A, Villa R, Bianchi FM, Busoli Badiale S, Angelinetta C. Maggioni D, et al. Clin Cosmet Investig Dermatol. 2020 Apr 21;13:299-308. doi: 10.2147/CCID.S240784. eCollection 2020. Clin Cosmet Investig Dermatol. 2020. PMID: 32368125 Free PMC article.
Improvement in ocular symptoms and signs in patients with Demodex anterior blepharitis using a novel terpinen-4-ol (2.5%) and hyaluronic acid (0.2%) cleansing wipe.
Messaoud R, El Fekih L, Mahmoud A, Ben Amor H, Bannour R, Doan S, Khairallah M. Messaoud R, et al. Clin Ophthalmol. 2019 Jun 20;13:1043-1054. doi: 10.2147/OPTH.S198585. eCollection 2019. Clin Ophthalmol. 2019. PMID: 31417235 Free PMC article.
Update on the management of rosacea.
Weinkle AP, Doktor V, Emer J. Weinkle AP, et al. Clin Cosmet Investig Dermatol. 2015 Apr 7;8:159-77. doi: 10.2147/CCID.S58940. eCollection 2015. Clin Cosmet Investig Dermatol. 2015. PMID: 25897253 Free PMC article.
An integral topical gel for cellulite reduction: results from a double-blind, randomized, placebo-controlled evaluation of efficacy.
Dupont E, Journet M, Oula ML, Gomez J, Léveillé C, Loing E, Bilodeau D. Dupont E, et al. Clin Cosmet Investig Dermatol. 2014 Feb 20;7:73-88. doi: 10.2147/CCID.S53580. eCollection 2014. Clin Cosmet Investig Dermatol. 2014. PMID: 24600240 Free PMC article.